Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could it be about to do the same with haemophilia B?
Shares in Solid Biosciences plunged yesterday after the FDA placed a clinical hold on the trial of its gene therapy for Duchenne muscular dystrophy (DMD) following a serious adverse reactions in one patient.
